SciSparc Ltd. (SPRC): Marketing Mix Analysis [Dec-2025 Updated]

You're looking at a company, SciSparc Ltd., that's defintely trying to reinvent itself before the money runs out. As an analyst who's seen this pivot game before, I can tell you the current marketing mix-the 4Ps-tells a story of aggressive transition: they're balancing a cannabinoid drug pipeline (SCI-110, SCI-210) with a commercial medical device, the MUSE™ system, and even dipping into quantum computing. Honestly, the numbers don't lie: H1 2025 saw only $0.461 million in sales against a $9.33 million net loss, meaning the stock price is running purely on hope and strategic announcements, not cash flow. Below, I break down exactly what Product, Place, Promotion, and Price look like for this clinical-stage firm making a hard pivot into commercial reality, so you can see where the real risk and reward lie.

SciSparc Ltd. (SPRC) - Marketing Mix: Product

SciSparc Ltd. offers a diversified product portfolio spanning clinical-stage pharmaceuticals, a recently acquired medical device technology, and consumer nutraceuticals, with the core value proposition residing in high-risk, high-reward intellectual property and clinical assets.

Cannabinoid-based drug pipeline

The pharmaceutical product development is centered on cannabinoid-based therapies for central nervous system disorders, managed through the majority-owned subsidiary, NeuroThera Labs Inc.

• SCI-110 targets Tourette syndrome, which is subject to a phase IIb clinical trial.
• SCI-110 also targets Alzheimer's disease and agitation; its phase II clinical trial has been completed.
• SCI-210 targets autism spectrum disorder (ASD) and status epilepticus; a randomized, double-blind and placebo-controlled trial commenced in the first quarter of 2024.
• The company has an agreement with Procaps for the commercial manufacture of SCI-110 palmitoylethanolamide oral tablets.
• The company also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial for SCI-110.

Commercial-stage MUSE™ system

SciSparc, via NeuroThera Labs Inc., signed a binding term sheet to acquire intellectual property rights for the MUSE™ system, a single-use endoscopic device for transoral fundoplication treatment of gastroesophageal reflux disease (GERD).

The acquisition structure involves issuing ordinary shares representing 19.99% of SciSparc's outstanding share capital to Xylo Technologies Ltd. upon closing.

Hemp-based nutraceuticals sold via the Online Sales segment

This segment includes various hemp-based products sold online, such as gummies, oil capsules, gel, and creams. The segment has demonstrated significant year-over-year growth in the trailing twelve months ending September 30, 2025.

SciSparc's trailing twelve-month revenue as of June 30, 2025, was $927K. Revenue for the twelve months ending September 30, 2025, reached $1.31M, representing a 187.98% increase year-over-year. For comparison, the annual revenue in 2024 was $1.31 million, a decrease of -54.64% from the 2023 revenue of $2.88 million.

Quantum computing bio data analytics capabilities

NeuroThera Labs entered a non-binding term sheet to acquire a 55% stake in an Israeli quantum computing bio data company.

• NeuroThera will secure the stake by allocating common shares representing 40% of NeuroThera's total shares on a non-diluted basis to the target company's existing shareholders.
• The initiative focuses on leveraging quantum computing for enhanced clinical analytics, including 3D protein modeling for AI drug discovery.

The core value is in high-risk, high-reward intellectual property (IP) and clinical assets

The company's valuation is heavily tied to the potential success of its development pipeline and acquired IP. The pharmaceutical assets were valued at approximately $11.6 million in December 2024. As of December 2, 2025, SciSparc Ltd.'s market capitalization was cited as approximately $2.98 million. The trailing twelve-month revenue as of September 30, 2025, was $1.31M.

SciSparc Ltd. (SPRC) - Marketing Mix: Place

Place, for SciSparc Ltd. (SPRC), involves distinct distribution strategies for its pharmaceutical pipeline assets and its consumer nutraceuticals division, all managed from its corporate headquarters in Tel Aviv, Israel.

Global Clinical Trials Network for Pharmaceutical Development Programs

The physical placement of SciSparc Ltd. (SPRC)'s pharmaceutical development is centered around active and completed clinical trial sites. The company's focus is on advancing its pipeline through established trial structures:

• SCI-110 for Tourette syndrome is subject to a phase IIb clinical trial.
• The phase II clinical trial for SCI-110 targeting Alzheimer's disease has been completed.
• The trial for SCI-210, targeting children with autism, commenced in the first quarter of 2024.

Direct-to-Consumer E-commerce Channels, Primarily Amazon.com, for Nutraceuticals

Distribution for the nutraceutical segment, primarily through its subsidiary SciSparc Nutraceuticals Inc., has historically relied on direct-to-consumer e-commerce, specifically the Amazon.com marketplace. For the CannAmide™ product, an exclusive license was granted for sales on the Amazon.com marketplace in Canada. The Wellution™ brand, which offers hemp-based products, was a top seller on Amazon.com.

Historical metrics related to this channel include:

• The leading parent ASIN for the Wellution™ brand, launched in 2019, received over 26,500 reviews.
• The total brand had accumulated over 40,000 product reviews as of September 2022.
• A prior distribution agreement included a minimum initial order requirement by the distributor of $100,000 of the Brand's products.

Strategic Focus and Commercialization Model for MUSE™ System Distribution

Following the binding term sheet to acquire the Intellectual Property for the single-use MUSE™ transoral fundoplication system, SciSparc Ltd. (SPRC) is establishing its physical market presence through a targeted partnership strategy. The company is explicitly targeting commercialization across North America, Europe, and Latin America.

The commercialization model for the MUSE™ system relies on securing exclusive partnerships with regional distributors, aiming to replicate a prior successful model in Greater China. That prior model, an agreement with a Shanghai-based medical instruments company in 2019, resulted in an $3 million up front payment to the IP owner.

The market SciSparc Ltd. (SPRC) is entering through this distribution strategy is substantial:

The company's ability to secure these regional distributors will be key to placing the MUSE™ system where the demand for minimally invasive GERD treatment exists. It's a strategy focused on leveraging local expertise for market penetration.

SciSparc Ltd. (SPRC) - Marketing Mix: Promotion

Promotion for SciSparc Ltd. (SPRC) is heavily weighted toward corporate actions and strategic announcements, which serve as the primary communication tools to the market, given that core pharmaceutical assets remain pre-commercial.

Primary promotion is through high-impact, high-risk strategic news announcements to the market. The company's promotional cadence is dictated by material corporate developments rather than sustained advertising campaigns. For instance, a significant stock movement of 22.95% occurred on Wednesday, November 26, 2025, directly following news flow. The stock price itself shows responsiveness to these announcements, having recently fluctuated between $2.39 to $3.06 within a few days. A recent trading day on Thursday, December 4, 2025, saw the stock gain 3.51%, closing at $1.77. The 52-week trading range has been wide, with a high of $8.90 and a low of $0.197.

Investor relations highlights strategic pivots (e.g., quantum computing, medical device acquisition) as catalysts. Investor relations efforts focus on framing major transactions and R&D advancements as value inflection points. The recent binding term sheet to acquire the MUSE™ system IP from Xylo Technologies Ltd. is a prime example of this focus. This transaction involves issuing shares representing 19.99% of SciSparc's capital to Xylo upon closing. Furthermore, SciSparc promotes its foray into advanced technology, such as targeting Quantum-Powered 3D Protein Modeling Technology to revolutionize AI Drug Discovery (announced October 23, 2025). The company also highlights the patent filing for a novel combination therapy with Clearmind Medicine targeting Weight Loss and Fatty Liver Disease (July 30, 2025).

The key promotional catalysts announced in late 2025 can be summarized as follows:

Stock price is largely driven by retail momentum and speculation on future IP value. The company's stock performance reflects a high sensitivity to news, often characteristic of micro-cap biotech speculation. The short sale ratio as of December 2, 2025, stood at 30.18%, suggesting active short interest alongside retail trading. Forecasts for the 2025 year-end price vary, with one model placing the stock between $2.18 and $2.19 per share, while another suggests an average price of $3.8966. The insider connections between SciSparc, N2OFF, and RVSN, sharing the same Investor Relations representative, Michal Efraty, suggest a coordinated communication strategy that can fuel retail momentum.

Leveraging Xylo Technologies' successful commercialization track record for the MUSE™ system. A core part of the promotion around the MUSE™ system acquisition is referencing Xylo's prior success to validate the IP's commercial potential. Xylo previously secured a $3 million upfront payment through a licensing agreement in Greater China back in 2019. SciSparc plans to replicate this proven model by pursuing exclusive distributor partnerships across North America, Europe, and Latin America. This move positions SciSparc to enter the global GERD device market, which a May 2025 report valued at $2.5 billion in 2024, projected to reach $3.03 billion by 2030 (CAGR of 3.24% 2025-2030).

Minimal traditional product marketing, as the core pharma assets are still pre-commercial. The promotional focus is clearly on corporate finance and M&A activity, not direct-to-consumer or physician marketing for its drug pipeline. The primary pharmaceutical assets, such as SCI-110 (for Tourette Syndrome, Alzheimer's Disease, and Agitation) and SCI-210 (for Autism Spectrum Disorder), are explicitly noted as being in the clinical trials development or pre-clinical stage. The only product with a confirmed market presence is CannAmide, which has a product license issuance from Health Canada for sale as a supplement in the nutraceuticals market.

SciSparc Ltd. (SPRC) - Marketing Mix: Price

Price, for SciSparc Ltd. (SPRC), is currently defined more by future potential and operational deficits than by established product sales, reflecting its clinical-stage focus.

The core pharmaceutical development assets, specifically SCI-110 for Tourette syndrome and SCI-210 for autism spectrum disorder, do not carry a commercial price tag as of late 2025. This absence of a price reflects a future-value pricing model, where value is derived from anticipated regulatory approval and subsequent market exclusivity, rather than current transaction revenue.

Current realized revenue is minimal and derived from a segment that is explicitly low-margin. For the first half of 2025 (H1 2025), SciSparc Ltd. (SPRC) reported sales revenue of only \$0.461 million. This revenue is sourced entirely from the Online Sales segment, which offers hemp-based wellness products.

The pricing strategy for the medical device portfolio, following the acquisition of the intellectual property rights for the MUSE™ system, indicates a high-value licensing approach. This is evidenced by the prior success of the system's previous owner in Greater China, which secured an upfront payment of \$3 million in 2019 for licensing rights. SciSparc Ltd. (SPRC) intends to replicate this high-value, upfront-payment licensing model in North America, Europe, and Latin America.

The financial reality of the current pricing structure and operational scale shows SciSparc Ltd. (SPRC) is operating at a substantial loss. The net loss for H1 2025 was reported at \$9.33 million.

The company's overall financial standing necessitates that its current market valuation remains tethered to speculative upside rather than current operational performance metrics. The financial data points illustrating this are:

• H1 2025 Sales Revenue: \$0.461 million
• H1 2025 Net Loss: \$9.33 million
• Implied EBITDA for a recent period: -\$12.41 million
• Prior Medical Device Upfront Payment (MUSE™ in Greater China): \$3 million

To provide a clearer picture of the financial context surrounding the pricing strategy, here is a comparison of key financial metrics from the H1 2025 results:

The pricing strategy for the pharmaceutical pipeline is entirely deferred, meaning the current pricing mechanism is limited to the low-margin online segment, which generated only \$0.461 million in H1 2025. The medical device strategy, conversely, targets high, lump-sum payments based on licensing precedents, such as the \$3 million received previously.

You're looking at a company where the price element is bifurcated: one part is non-existent (pharma assets), and the other is low-margin retail, while the high-value pricing is entirely contingent on future licensing deals for the acquired device portfolio.